Mr. Pearson was appointed CEO of Carrick in July 2019 and has over 30 years experience in healthcare, 25 of which have been in the biotech industry. Most recently he served as Executive Vice President and Chief Financial Officer for TESARO Inc., a publicly held oncology-focused biopharmaceutical company, since 2014. While at TESARO, Mr. Pearson successfully raised over $1.6bn in funding, and helped build the company from 60 to over 850 people before the sale to GSK in January of 2019 for $5bn. His leadership helped TESARO gain regulatory approval and commercialize two cancer drugs in the U.S. and Europe. Prior to that, he was Executive Vice President and Chief Financial Officer at Catalyst Health Solutions, a publicly traded pharmacy benefit manager with over $5 bn in revenues until the company was acquired by SXC Health Solutions (now part of United Healthcare) in 2012. Prior to Catalyst, Mr. Pearson worked for MedImmune in various finance roles from 1998 through its sale to AstraZeneca in 2007 for $16bn. He continued employment with MedImmune after the acquisition through 2011 as Executive Vice President and Chief Financial Officer where he had functional responsibility for finance, information technology, and strategic planning.
In addition to Carrick’s board of directors, Mr. Pearson leverages his passion for improving the lives of patients with critical diseases by serving as Chairman of GlycoMimetics, Inc. Mr. Pearson, a CPA, holds a B.S. in Business Administration from the University of Delaware, a B.S. in Accounting from the University of Maryland University College, and an M.S. in Finance from Loyola University.
Dr Bahl has 25 years of international Pharmaceutical experience leading collaborations in US, Japan, and Europe. His previous roles were with Eli Lilly (Vice President of External Innovation), AstraZeneca (Vice President Head of R&D New Opportunities) and Glaxo.
Dr Bahl did his first degree in Pharmacy at Kings College London, trained as a pharmacist at John Radcliffe Hospital Oxford and then a PhD in Immunology at University College London (UCL). Dr Bahl has delivered over 10 compounds into clinical development from his leadership of drug discovery projects in R&D. Dr Bahl has also helped in establishing pioneering collaboration with the Medical Research Council and NIH/NCATs in drug repositioning. Within Eli Lilly he led collaborations with the Chorus Unit and Lilly’s Venture funds, this resulted in creation of several new project focused companies.
With more than 25 years of experience in the biotechnology industry, Jenny is dedicated to building Carrick’s innovative portfolio and accessing potential new treatments that can have a major impact on the lives of patients.
She is a former Global Transaction Director for AstraZeneca where she had responsibility for leading the evaluation and negotiation of business development transactions including in-licensing, out-licensing, collaborations, M&A and divestments across a number of therapy areas including Oncology and Respiratory and Inflammation.
Previous positions at AstraZeneca included Head of Business Development Japan based in Osaka, responsible for all Japanese partnering activities and Head of transactions China and Asia, based in Shanghai.
Jenny has a broad commercial and finance background and is a qualified Chartered Global Management Accountant (CGMA)
Dr Stuart McIntosh has over 27 years medical and clinical development research experience with senior medical roles in biotech and large pharma at AstraZeneca/MedImmune, Aimmune and Takeda. Dr McIntosh has worked in both small molecule oncology and large molecule immune-oncology, including PD-L1(durvalumab IMFINZI) and EGFR (gefitinib IRESSA) targeted therapies across all stages of development and marketing. Experience includes Global Medical Lead for phase III programs in lung and prostate cancer and pre- and post-marketing regulatory authority interactions and reporting in US, EU and Asia – including Japan and China. Prior to joining Carrick he was VP Clinical Development at Aimmune Therapeutics with responsibility for all European Clinical Science and Operations activities.
A UK trained physician Dr McIntosh qualified in 1995 and practiced in the UK and Australia becoming a Member of the Royal College of Surgeons of Edinburgh. Following time in academia gaining his research doctorate at the University of Newcastle he joined the pharmaceutical industry. He holds the Diploma of Pharmaceutical Medicine and is a Fellow of the Faculty of Pharmaceutical Medicine, Royal College of Physicians London. He has completed higher medical training with entry on the General Medical Council Specialist Register under Pharmaceutical Medicine.
VP CMC Manufacturing
Paul McGee has 27 years of working on CMC programmes from early development to commercial supply. His previous roles include Head of CMC at Heptares Therapeutics, Senior Director Chemical Development at Shire Pharmaceuticals, Site Head Aptuit and SVP, Chemical Development at Evotec.
Paul studied Chemistry at Oxford University and following completion of his studies, moved into industry in the early 1990’s, working for chemistry services-based organisations and leading operations involving 150 employees, delivering on >1000 projects. For the last 10 years Paul has been responsible for management of drug substance and drug product development programmes and supply of investigation medicinal products in a virtual environment employing external service providers for research, development and manufacture.
VP Business Development & Alliance Management
Anthony has over 30 years of experience in drug discovery with a primary focus in oncology, immune-oncology and fibrosis. He has held Director and Senior level positions spanning both scientific and commercial roles. He has led multiple successful INDs across both small molecules and biologics and has extensive experience from target identification through to clinical studies (Ph1/2). He has direct experience of and leading M&As, in-licensing, financing through IPOs, VCs, private investment and has founded a number of start-up Biotechs. Previous roles include CSO BerGenBio, Scientific Director CellCentric, Director of Business Management Cancer Research Technology and Director of Biology at Piramed. He is currently Expert in Residence for Drug Discovery at Oxford University and sits on the advisory boards of two European Biotechs. He holds a D.Phil in Biochemistry from University of Oxford and an MBA with distinction from Oxford Brookes University.